Altria Group (MO)
(Delayed Data from NYSE)
$45.95 USD
-0.10 (-0.22%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $45.96 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.95 USD
-0.10 (-0.22%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $45.96 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Altria (MO) Up 11% in 3 Months: Is There More Room for Growth?
by Zacks Equity Research
Altria (MO) is benefiting from its focus on expanding smoke-free alternatives and strong pricing power amid low cigarette volumes.
Altria Group, Inc. (MO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Altria (MO) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Altria (MO) concluded the recent trading session at $46.42, signifying a -0.06% move from its prior day's close.
Altria (MO) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $46.45, moving +1.55% from the previous trading session.
Altria's (MO) Smoke-Free Growth Underway With Latest FDA Nod
by Zacks Equity Research
Altria's (MO) NJOY obtains authorization from the U.S. Food and Drug Administration for menthol e-vapor products.
Altria (MO) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Altria (MO) closed at $44.80, indicating a +0.22% shift from the previous trading day.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) concluded the recent trading session at $45.87, signifying a -1.14% move from its prior day's close.
Investors Heavily Search Altria Group, Inc. (MO): Here is What You Need to Know
by Zacks Equity Research
Altria (MO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Here is What to Know Beyond Why Altria Group, Inc. (MO) is a Trending Stock
by Zacks Equity Research
Altria (MO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Altria (MO) Navigates Hurdles on Pricing, Smoke-Free Strength
by Zacks Equity Research
Altria (MO) gains from its pricing power and focus on smoke-free products to navigate market uncertainties like low cigarette volumes.
Is SPDR S&P Global Dividend ETF (WDIV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for WDIV
Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).
Zacks Industry Outlook Philip Morris, Altria and British American Tobacco
by Zacks Equity Research
Philip Morris, Altria and British American Tobacco have been highlighted in this Industry Outlook article.
3 Tobacco Stocks Worth Watching Amid Industry Challenges
by Vrishali Bagree
The Zacks Tobacco industry companies have been grappling with soft cigarette volume and elevated cost hurdles. However, pricing power and strength in smoke-free products work well for Philip Morris (PM), Altria Group (MO) and British American Tobacco (BTI).
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHD
Is Trending Stock Altria Group, Inc. (MO) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPHD
Altria Group, Inc. (MO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Altria (MO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Has Altria Group (MO) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Here is how Altria (MO) and Procter & Gamble (PG) have performed compared to their sector so far this year.
Altria's (MO) Q1 Earnings Miss Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Altria's (MO) first-quarter 2024 results reflect lower cigarette shipment volumes as a result of macroeconomic pressure on ATC behavior. However, pricing remains an upside.
Compared to Estimates, Altria (MO) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Altria (MO) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Altria (MO) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of -0.86% and 0.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?